

# Gianluca Masi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1595248/publications.pdf>

Version: 2024-02-01

130  
papers

10,169  
citations

117625

34  
h-index

34986

98  
g-index

132  
all docs

132  
docs citations

132  
times ranked

11310  
citing authors

#	ARTICLE	IF	CITATIONS
1	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	13.7	2,771
2	Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. <i>Journal of Clinical Oncology</i> , 2007, 25, 1670-1676.	1.6	1,083
3	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1609-1618.	27.0	845
4	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2622-2629.	1.6	402
5	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , 2017, 18, 1159-1171.	10.7	293
6	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	7.1	280
7	Derazantinib (ARQ 087) in advanced or inoperable <i>FGFR2</i> gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	6.4	279
8	Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 1247-1254.	1.6	250
9	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology, The</i> , 2010, 11, 845-852.	10.7	234
10	High Concordance of <i>KRAS</i> Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. <i>Oncologist</i> , 2008, 13, 1270-1275.	3.7	218
11	Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases. <i>Annals of Surgery</i> , 2009, 249, 420-425.	4.2	213
12	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2020, 21, 497-507.	10.7	196
13	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 21-30.	6.3	160
14	Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2006, 13, 58-65.	1.5	156
15	Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 4006-4014.	1.6	148
16	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3314-3324.	1.6	139
17	First-line chemotherapy for mCRC—a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619.	27.6	138
18	Role of <i>NRAS</i> mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015, 136, 83-90.	5.1	126

#	ARTICLE	IF	CITATIONS
19	Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1427-1434.	1.6	124
20	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	3.7	94
21	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	7.1	87
22	Anti-HER agents in gastric cancer: from bench to bedside. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 369-383.	17.8	73
23	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011, 11, 247.	2.6	69
24	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009, 9, 303.	2.6	66
25	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2719-2725.	1.8	66
26	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012, 15, 275-286.	7.2	61
27	Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity. <i>Journal of Clinical Oncology</i> , 2007, 25, 1816-1818.	1.6	56
28	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017, 73, 74-84.	2.8	54
29	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	2.3	54
30	Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3456-3462.	1.6	51
31	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	3.7	46
32	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021, 41, 1389-1397.	3.9	45
33	The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. <i>Annals of Surgical Oncology</i> , 2017, 24, 2465-2473.	1.5	42
34	Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1305-1314.	2.0	41
35	First-line therapy for mCRC – the influence of primary tumour location on the therapeutic algorithm. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 113-113.	27.6	35
36	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33

#	ARTICLE	IF	CITATIONS
37	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. <i>Hepatology Research</i> , 2021, 51, 1229-1241.	3.4	33
38	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 243-251.	4.4	31
39	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	7.7	31
40	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. <i>Cancer Management and Research</i> , 2021, Volume 13, 9379-9389.	1.9	31
41	Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. , 1999, 86, 470-476.		30
42	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 318-323.	6.4	29
43	Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases. <i>Clinical Colorectal Cancer</i> , 2013, 12, 188-194.	2.3	28
44	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	2.6	28
45	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014, 9, 205-214.	3.6	27
46	HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. <i>Oncologist</i> , 2020, 25, 886-893.	3.7	27
47	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	2.8	25
48	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019, 110, 32-41.	2.8	25
49	Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. <i>World Journal of Gastroenterology</i> , 2014, 20, 6081.	3.3	24
50	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. , 2021, 9, e002996.		24
51	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	1.6	24
52	A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed. <i>Clinical Cancer Research</i> , 2004, 10, 1657-1663.	7.0	23
53	Infusions of Fluorouracil and Leucovorin: Effects of the Timing and Semi-Intermittency of Drug Delivery. <i>Oncology</i> , 1999, 57, 195-201.	1.9	22
54	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 315-320.	1.1	21

#	ARTICLE	IF	CITATIONS
55	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	4.5	20
56	Minor-but-Complex Liver Resection. <i>Medicine (United States)</i> , 2015, 94, e1188.	1.0	19
57	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , 2017, 117, 315-321.	6.4	19
58	Palliative treatment of unresectable metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 63-77.	1.8	18
59	Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?. <i>Oncology</i> , 2014, 86, 191-198.	1.9	18
60	Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e61-e72.	2.3	18
61	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. <i>Tumori</i> , 2006, 92, 384-388.	1.1	17
62	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. <i>Clinical Colorectal Cancer</i> , 2012, 11, 71-76.	2.3	17
63	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-657.	1.6	17
64	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020, 12, 1022.	3.7	16
65	Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 7-14.	2.3	15
66	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020, 15, 115-126.	3.6	15
67	Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 159-163.	2.3	14
68	Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. <i>Future Oncology</i> , 2011, 7, 1299-1323.	2.4	14
69	Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3487-3488.	1.6	14
70	Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. <i>Future Oncology</i> , 2016, 12, 901-908.	2.4	14
71	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	1.1	14
72	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019, 164, 94-105.	4.4	14

#	ARTICLE	IF	CITATIONS
73	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , 2021, 23, 915-920.	0.3	14
74	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 585-593.	2.3	13
75	Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. <i>Future Oncology</i> , 2014, 10, 285-304.	2.4	13
76	Techniques of parenchyma-sparing hepatectomy for the treatment of tumors involving the hepatocaval confluence: A reliable way to assure an adequate future liver remnant volume. <i>Surgery</i> , 2017, 162, 483-499.	1.9	13
77	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	2.8	13
78	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1 $\alpha$ Final results of the ALICE-2 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-280.	1.6	13
79	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. <i>Pharmacogenomics</i> , 2008, 9, 55-69.	1.3	12
80	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. <i>Current Cancer Drug Targets</i> , 2010, 10, 37-45.	1.6	12
81	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1283-1292.	2.4	12
82	Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	2.5	12
83	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 314-317.	2.3	12
84	First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. <i>Current Opinion in Oncology</i> , 2008, 20, 459-465.	2.4	11
85	Pharmacoeugenetics in gastrointestinal tumors em MGMT em methylation and beyond. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 170-180.	1.8	11
86	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 874.	2.6	10
87	5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer. <i>Oncology</i> , 2001, 61, 28-35.	1.9	9
88	Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 132-134.	2.4	9
89	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	3.7	9
90	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	6.4	9

#	ARTICLE	IF	CITATIONS
91	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. <i>Cancer Treatment Reviews</i> , 2022, 106, 102382.	7.7	9
92	Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. <i>International Journal of Biological Markers</i> , 2015, 30, 65-72.	1.8	8
93	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2018, 36, 709-714.	2.6	8
94	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 167, 23-31.	2.8	8
95	Oral Doxifluridine in Advanced Hepatocellular Carcinoma: A Phase II Study. <i>Oncology</i> , 2000, 59, 204-209.	1.9	7
96	A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. <i>Oncology</i> , 2012, 82, 75-82.	1.9	7
97	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	2.3	7
98	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190.	6.4	7
99	Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. <i>Tumori</i> , 2006, 92, 384-8.	1.1	7
100	Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers. <i>Tumori</i> , 2015, 101, 139-143.	1.1	6
101	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2022, 103, 102326.	7.7	6
102	Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 165, 116-124.	2.8	6
103	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	6.4	6
104	Refractory neuroendocrine tumor response to liposomal doxorubicin and capecitabine. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 670-674.	27.6	5
105	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 559-566.	2.3	5
106	Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. <i>Cancer Biology and Therapy</i> , 2013, 14, 467-468.	3.4	5
107	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. <i>Oncology</i> , 2016, 91, 283-288.	1.9	5
108	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	2.8	5

#	ARTICLE	IF	CITATIONS
109	Optimal approach to potentially resectable liver metastases from colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1533-1539.	2.4	4
110	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. <i>Hepatology Research</i> , 2021, 51, 796-802.	3.4	4
111	Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. <i>Epigenomics</i> , 2022, 14, 507-517.	2.1	4
112	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 519-531.	3.1	3
113	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019, 4, e000496.	4.5	3
114	Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. <i>In Vivo</i> , 2020, 34, 2061-2066.	1.3	3
115	Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1741-1750.	1.9	3
116	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	3
117	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72.	2.8	3
118	Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?. <i>Updates in Surgery</i> , 2022, 74, 1327-1335.	2.0	3
119	5-Fluorouracil Administered as a 48-Hour Semiintermittent Infusion in Combination With Leucovorin, Cisplatin and Epirubicin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 101-105.	1.3	2
120	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	7.7	2
121	Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14577-e14577.	1.6	2
122	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3664-TPS3664.	1.6	2
123	Chemotherapy intensification. <i>Current Colorectal Cancer Reports</i> , 2007, 3, 116-122.	0.5	0
124	Long-Term Outcome of Unresectable Metastatic Colorectal Cancer: Does "Adjuvant" Chemotherapy Play a Role After Resection?. <i>Annals of Surgery</i> , 2009, 250, 655.	4.2	0
125	Prognostic Value of CD133 Caused by Mutant K-Ras and B-Raf" Letter. <i>Clinical Cancer Research</i> , 2012, 18, 4473-4473.	7.0	0
126	Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?. <i>Colorectal Cancer</i> , 2012, 1, 397-411.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	0.5	0
128	About the Recently Published Paper on JAMA Oncology "Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial" CardioVascular and Interventional Radiology, 2020, 43, 1418-1419.	2.0	0
129	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Targeted Oncology, 2021, 16, 653-661.	3.6	0
130	First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients. , 2009, , 285-293.		0